TME Pharma N.V. · EURONEXT:ALTME

TME Pharma — NOXXON Pharma — Technical Presentation (November 2021)

38 slides from TME Pharma's technical presentation, Nov 23, 2021

  1. Slide 1: NOX-A12 & Radiotherapy Combination: A New Approach to Treating Brain Cancer

    KOL WEBINAR WITH DR. FRANK GIORDANO NOX-A12 & RADIOTHERAPY COMBINATION: A DIFFERENTIATED AND PROMISING NEW APPROACH TO TREATING BRAIN CANCER November 23, 2021 | 8:00 AM EST / 2:00 PM CET © NOXXON Pharma 1

  2. Slide 2: Webinar Presenters

    WEBINAR PRESENTERS MODERATOR PRESENTERS Guillaume van Dr. Frank Giordano Aram Mangasarian Renterghem Chair & Director CEO Managing Director Radiation Oncology Dept. NOXXON Pharma LifeSci Advisors University Hospital Bonn Lead investigator of NOX-A12 GLORIA Phase 1/2 study 2

  3. Slide 3: Forward Looking Statements

    Forward Looking Statements The information and opinions contained in this representatives, or any of their respective directors, being accurate. This presentation contains forward presentation and any other information discussed at officers, employees, direct or indirect shareholders, looking statem

  4. Slide 4: Introductory remarks on NOXXON Pharma

    Introductory remarks on NOXXON Pharma Aram Mangasarian CEO NOXXON Pharma 4

  5. Slide 5: About NOXXON: Strong Value Proposition Through Differentiated Pipeline Targeting the TME

    ABOUT NOXXON: Strong Value Proposition Through Differentiated Pipeline Targeting the TME Clinical stage Expert in Tumor Focus on 2 large orphan Robust Upcoming biotech Microenvironment cancer indications commercial Catalysts company protection ~$6.5bn Addressable Market Mission to improve In brain c

  6. Slide 6: Treating Seed and Soil: Targeting CXCL12 in the Glioblastoma Tumor Microenvironment

    Treating Seed and Soil: Targeting CXCL12 in the Glioblastoma Tumor Microenvironment Frank A. Giordano, MD Professor of Radiation Oncology Director and Chair, Department of Radiation Oncology University Hospital Bonn Lead investigator of NOX-A12 GLORIA Phase 1/2 study

  7. Slide 7: Brain tumor incidences (primary brain tumors)

    Brain tumor incidences (primary brain tumors) California Dept. of Public Health, 2008

  8. Slide 8: A case to remember

    A case to remember ➢ 45 y/o female patient with a history of MS ➢ underwent MRT q3mo (for MS), last scan was before Xmas 2014 ➢ came to ER in April 2014: progressive vertigo, nausea and muscle weaknesses

  9. Slide 9: Standard of care for GBM: components

    Standard of care for GBM: components Surgery or Biopsy Radiotherapy Maintenance + Chemotherapy Chemotherapy

  10. Slide 10: Standard of care for GBM: outcome

    Standard of care for GBM: outcome Stupp et al., 2005

  11. Slide 11: Role of MGMT expression in GBM

    Role of MGMT expression in GBM PROM DNAMGMT CH3 TMZ (Methylhydrazin) Apoptosis

  12. Slide 12: Role of MGMT expression in GBM

    Role of MGMT expression in GBM PROM DNAMGMT CH3 TMZ (Methylhydrazin) Apoptosis

  13. Slide 13: Role of MGMT expression in GBM

    Role of MGMT expression in GBM PROM DNAMGMT CH3 83% surgery TMZ 17% biopsy (Methylhydrazin) Hegi NEJM 2005 Thon J Neurol 2017 Apoptosis

  14. Slide 14: GBM recurrence patterns

    GBM recurrence patterns local 97-99% combined ~1-3% distant <1% Choucair et al, 1986 Wallner et al, 1989 Gaspar et al, 1992 Petrecca et al, 2013

  15. Slide 15: Reasons for rapid local recurrence

    Reasons for rapid local recurrence Giordano Neurosurgery 2019 - residual tumor cells remain even after “perfect” (or supramaximal) surgery - GB stem cells show a high degree of radio- and chemoresistance - highly effective revascularization after radiotherapy

  16. Slide 16: Reasons for rapid local recurrence

    Reasons for rapid local recurrence Giordano Neurosurgery 2019 - residual tumor cells remain even after “perfect” (or supramaximal) surgery - GB stem cells show a high degree of radio- and chemoresistance - highly effective revascularization after radiotherapy

  17. Slide 17: Mechanism of revascularization after RT

    Mechanism of revascularization after RT Chemoattraction towards gradient CXCR4+ SDF-1 (=CXCL12) CXCR4+ myeloid cells MP/TAM (microglia is CXCR4 negative) monocytes (would not persist in intact brain) CD11b+CD14+CD33+ myeloid-derived suppressor cells Greenfield J Clin Invest 2010 BMDC, Bone Marrow-De

  18. Slide 18: Mechanism of revascularization after RT

    Mechanism of revascularization after RT

  19. Slide 19: Targeting CXCL12 in other cancers

    Targeting CXCL12 in other cancers mRNA expression of CXCL12 in various cancers Broad Institute Cancer Cell Line Encyclopedia

  20. Slide 20: Targeting CXCL12 in other cancers

    Targeting CXCL12 in other cancers mRNA expression of CXCL12 in various cancers Broad Institute Cancer Cell Line Encyclopedia

  21. Slide 21: Strong pre-clinical evidence for radiotherapy + NOX-A12

    Strong pre-clinical evidence for radiotherapy + NOX-A12 EFFECTS OF TREATMENTS Autochthonous brain tumor model in rats Radiotherapy • Spontaneous tumor development in immuno-competent at day 0 host • Diversity of tumor cell types with therapeutic resistance comparable to human situation • Refractory

  22. Slide 22: Background and rationale

    Background and rationale Olaptesed pegol (OLA, NOX-A12) RNA Spiegelmer (L-stereoisomer) binds & neutralizes Ceradini, Nat Med 2004 Greenfield, J Clin Invest. 2010 Kioi, J Clin Invest. 2010 OLA NOX-A12 CXCL12 Liu, Neuro Oncol. 2014 CXCR4, C-X-C Motif Chemokine Receptor 4 (receptor for CXCL12) BMDC, b

  23. Slide 23: GLORIA Phase I/II Trial

    GLORIA Phase I/II Trial Key inclusion criteria: RT • Newly-diagnosed supratentorial 60 Gy (2 Gy x 30) glioblastoma WHO IV 40.05 Gy (2.67 Gy x 15) • unmethylated MGMT promoter • Incomplete resection/biopsy only OLA (NOX-A12) Follow- • ECOG ≤ 2 continuous i.v. infusion at three doses (200, 400, 600 mg

  24. Slide 24: CONSORT of GLORIA and controls

    CONSORT of GLORIA and controls GLORIA Matched Imaging Control Cohort** 11 screened 25 screened 2 excluded 9 enrolled 12 no advanced MRI RT + 200 mg/week 3 cohort 1 9 advanced MRI 13 advanced MRI OLA RT + 400 mg/week 3 cohort 2 OLA 1 CODEX* 7 CODEX* RT + 600 mg/week 3 cohort 3 OLA 21 no paired sample

  25. Slide 25: Primary EP: Safety (AE relationships)

    Primary EP: Safety (AE relationships) RT All: n=170 n = 29 cut-off date: 10/15/2021 20 2 5 OLA 2 n = 17 38 9* 4 Tumor-related n = 49 *OLA-only related AE GGT increased G3 2 x ALT increased G2 Dyspnea G1 3 x Leukocytosis G1 Paresthesia G1 Pyrexia G1 - 25 -

  26. Slide 26: Best response under OLA (volume of T1 enhancing lesions)

    Best response under OLA (volume of T1 enhancing lesions) VT1 GLORIA Independent Central Review VT1 Matched Imaging Control Cohort 300 (n=9) (n=13) 300 Max. change from baseline [%] Max. change from baseline [%] 200 200 100 100 PD PD 0 SD SD > 300 % PR PR -100 -100 p=0.0026 Non-parametric Mann Whitne

  27. Slide 27: Best response in cellularity and tumor perfusion under OLA

    Best response in cellularity and tumor perfusion under OLA ADC mean ADC mean rCBV mean FTBhigh (Independent Central Review, n=9) rCBV (Independent mean Central Review, n=9) FTB (Independent highReview, n=9) Central 300 300 300 Max. change from baseline [%] Max. change from baseline [%] Max. change f

  28. Slide 28: Exemplary response to RT/OLA

    Exemplary response to RT/OLA OLA / NOX-A12 TMZ RT W26 Baseline W9 W18 W34 W39 C1-003 OLA / NOX-A12 Baseline RT W26 W49 W9 W18 C1-001 re-surgery for suspected PD CODEX path report: Ki67<5% - 28 -

  29. Slide 29: CODEX: RT/OLA reduces CXCL12 levels in the tumor endothelium

    CODEX: RT/OLA reduces CXCL12 levels in the tumor endothelium Baseline Post RT / under OLA CXCL12+ cells Patient C1-001 GLORIA 20 50 C1-001 Out of CD31+ cells (%) Out of total cells (%) 40 15 DAPI CD31 30 Baseline Post RT/TMZ CXCL12 10 20 5 10 0 0 e e 12 12 in in A A el el X- X- as as O O B B Referen

  30. Slide 30: CODEX: RT/OLA reduces tumor cell proliferation

    CODEX: RT/OLA reduces tumor cell proliferation Baseline Post RT / under OLA Proliferating cells GLORIA Patient C1-001 C1-001 15 Out of total cells (%) DAPI 10 Baseline Post RT/TMZ Ki67 5 0 e 12 in A References el X- as O Baseline Post RT/TMZ/NIVO B N er nd /u T R st Po Images show areas of pathologi

  31. Slide 31: CODEX: Cytotoxic T cell infiltration and activation

    CODEX: Cytotoxic T cell infiltration and activation Baseline Post RT / under OLA CD8+ GNZB+ CD8+ Patient C1-001 Patient C1-001 GLORIA 2.0 0.8 Out of total cells (%) C1-001 1.5 0.6 DAPI 1.0 0.4 CD8 Baseline Post RT/TMZ GNZB 0.5 0.2 0.0 0.0 12 / e 12 / e X- RT in X- RT in el el N st as N st as A A Po

  32. Slide 32: CODEX: Cytotoxic T cell infiltration and activation

    CODEX: Cytotoxic T cell infiltration and activation Baseline Post RT / under OLA CD8+ GNZB+ CD8+ Patient C1-001 Patient C1-001 GLORIA 2.0 0.8 Out of total cells (%) C1-001 1.5 0.6 1.0 0.4 0.5 0.2 Whole slide spatial Analysis 0.0 0.0 12 / e 12 / e X- RT in X- RT in Baseline Post RT / under OLA el el

  33. Slide 33: Conclusions – GLORIA Study

    Conclusions – GLORIA Study • Combined RT + OLA (NOX-A12) treatment is feasible and safe • Initial promising efficacy signals o 8 out of 9 patients showed a response as per volume of T1-contrast (2 x PR) o reduced cellularity in 8 out of 9 patients o reduced perfusion 7 out of 9 patients • Tissue ana

  34. Slide 34: Acknowledgements

    Acknowledgements UKB Radiation Oncology UKB Neuropathology Uni Heidelberg Julian P. Layer Thorsten Pietsch UH Mannheim Katja Klever Lea Friker Elena Sperk Katharina Sahm UKB Exp. Oncology UC London Michael Platten Michael Hölzel Sotirios Bisdas Sonia Leonardelli UH Leipzig Roberta Turiello UKB Neuro

  35. Slide 35: Expansion Cohorts of Phase 1/2 Trial in Brain Cancer

    Expansion Cohorts of Phase 1/2 Trial in Brain Cancer Q4 2022 2021 Newly diagnosed brain Cohort Complete tumor resection cancer (glioblastoma) A NOX-A12 + RT MGMT promoter unmethylated population: chemotherapy will be Cohort Incomplete tumor resection B NOX-A12 + RT + anti-VEGF ineffective, so not us

  36. Slide 36: Next Step: Pivotal Trial in 1st line MGMT Promoter Unmethylated Patients

    Next Step: Pivotal Trial in 1st line MGMT Promoter Unmethylated Patients – 2025 Read-out Target Target Pivotal Study in Start Completion newly diagnosed brain cancer 2022 2025 (glioblastoma) Treatment until MGMT promoter Radiotherapy + NOX-A12 progression to unmethylated population: assess: chemothe

  37. Slide 37: Q&A Session

    Q&A Session Dr. Frank Giordano Aram Mangasarian Chair & Director CEO Radiation Oncology Dept. NOXXON Pharma University Hospital Bonn Lead investigator of NOX-A12 GLORIA Phase 1/2 study 37

  38. Slide 38: Thank you!

    Thank you! Contact Us: noxxon@noxxon.com 38

NOXXON Pharma — Technical Presentation (November 2021) on 6ix